Why there is no routine screening for pancreatic cancer, and what raises the risk

Pancreatic cancer occupies an unusual place in cancer control: it is uncommon, but among the most lethal of the common-enough cancers, and there is no routine test to catch it early. That absence is not an oversight. The US Preventive Services Task Force has looked at the question twice and both times recommended against screening the general public — a conclusion that says as much about the limits of screening as it does about the disease.

An uncommon cancer with an outsized death toll

The Task Force puts the age-adjusted incidence at 12.9 cases per 100,000 person-years and the death rate at 11.0 per 100,000 — a gap that narrow is the whole story of the disease [s1]. Because the prognosis is so poor, nearly everyone who is diagnosed dies of it, and pancreatic cancer is already the third most common cause of cancer death in the United States [s1]. Incidence is rising by roughly 0.5 to 1.0 percent a year, and it is projected to become the second-leading cause of cancer death by 2030 [s2]; the American Cancer Society similarly recorded pancreatic incidence increasing about 0.6 to 1 percent annually in its most recent statistics [s4]. Worldwide, the five-year survival rate has stood at around 9 percent [s3].

The reason is late diagnosis. Patients seldom show symptoms until the cancer has reached an advanced stage [s3], and by the time it is found, most disease is locally advanced, roughly 30 to 35 percent, or metastatic, roughly 50 to 55 percent, with only about 10 to 15 percent resectable at presentation [s2]. Surgery offers the best chance of long-term control, so a stage distribution that skewed toward inoperable disease is most of why the cancer is so deadly.

Why guidelines say not to screen

Given all that, screening might seem obviously worthwhile. The evidence says otherwise. The Task Force found no evidence that screening asymptomatic adults, or treating cancers found by screening, improves survival, and concluded that any benefit could be no greater than small [s1]. Against that, it found the harms — from false positives, and from the surgery and complications that can follow — to be at least moderate [s1]. Weighing a benefit bounded as small against harms bounded as at least moderate, it recommended against screening the general population, its grade D [s1].

The problem is partly statistical. When a disease is uncommon, most positive results from a screening test in the general population are false, and a false positive for pancreatic cancer can lead to invasive investigation of the pancreas, an organ where procedures carry real risk. The epidemiology literature reaches the same conclusion: screening large groups is not considered useful for detecting the disease early, though screening of tightly targeted groups, especially people with a strong family history, is being evaluated [s3]. That distinction — general population no, defined high-risk groups maybe — is where the active research sits.

The risk factors that are established

Primary prevention, not screening, is where the leverage is [s3]. The identified risk factors include tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, increasing age, ethnicity, family history and inherited genetic factors, Helicobacter pylori infection, non-O blood group, and chronic pancreatitis [s3]. Several of those — smoking, excess weight, alcohol — are modifiable, which is where the epidemiologists place the emphasis. Others, such as age, family history and inherited syndromes, are not, but they are what define the high-risk groups that targeted surveillance research is aimed at.

What this means for a reader

There is no early-warning test to ask for, and no symptom that reliably signals pancreatic cancer early, because early disease usually produces none [s3]. That makes two things useful to hold onto. First, the modifiable risk factors are the same ones that lower risk for several other cancers, so they are worth acting on regardless. Second, a person with a strong family history of pancreatic cancer or a known hereditary cancer syndrome is in a different category from the general public, and whether surveillance is appropriate for them is a specialist question, not a general-screening one. Anyone with persistent, unexplained symptoms — including new digestive problems, jaundice or weight loss they cannot account for — should be assessed by a clinician, who can decide what, if any, investigation is warranted. That is a reason to seek care, not a diagnosis.

Sources

• [s1] Screening for Pancreatic Cancer: USPSTF Reaffirmation Recommendation Statement, JAMA, 2019-08-06
• [s2] Pancreatic Cancer: A Review, JAMA, 2021-09-01
• [s3] Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors, World Journal of Oncology, 2019-02-26
• [s4] Cancer statistics, 2024, CA: A Cancer Journal for Clinicians, 2024-01-17